Antifungal Effect of All-trans Retinoic Acid against *Aspergillus fumigatus* In Vitro and in a Pulmonary Aspergillosis In Vivo Model

Elena Campione,a Roberta Gaziano,b Elena Doldo,c Daniele Marino,b Mattia Falconi,d Federico Iacovelli,d Daniela Tagliaferri,a Lucrezia Pacello,a Luca Bianchi,a Caterina Lanna,a Luigi Aurisicchio,e Federica Centofanti,f Paolo Di Francesco,b Ilaria Del Principe,g Francesca Del Bufalo,f Franco Locatelli,f Enrico Salvatore Pistoia,b Emanuele Marra,a Augusto Orlandi

Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

Anatomic Pathology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

Department of Biology, University of Rome Tor Vergata, Rome, Italy

Takis S.r.l., Rome, Italy

Department of Haematology, Oncology and Stem Cell Transplantation, Bambino Gesù Children’s Hospital (IRCSS), Rome, Italy

Department of Haematology, University of Rome Tor Vergata, Rome, Italy

Elena Campione and Roberta Gaziano contributed equally as first authors to this work, and Emanuele Marra and Augusto Orlandi contributed equally as last authors. Elena Campione and Augusto Orlandi conceived the research, while all other authors performed the research.

ABSTRACT  *Aspergillus fumigatus* is the most common opportunistic fungal pathogen and causes invasive pulmonary aspergillosis (IPA), with high mortality among immunosuppressed patients. The fungistatic activity of all-trans retinoic acid (ATRA) has been recently described *in vitro*. We evaluated the efficacy of ATRA *in vivo* and its potential synergistic interaction with other antifungal drugs. A rat model of IPA and *in vitro* experiments were performed to assess the efficacy of ATRA against *Aspergillus* in association with classical antifungal drugs and *in silico* studies used to clarify its mechanism of action. ATRA (0.5 and 1 mM) displayed a strong fungistatic activity in *Aspergillus* cultures, while at lower concentrations, synergistically potentiated fungistatic efficacy of subinhibitory concentration of amphotericin B (AmB) and posaconazole (POS). ATRA also enhanced macrophagic phagocytosis of conidia. In a rat model of IPA, ATRA reduced mortality similarly to posaconazole. Fungistatic efficacy of ATRA alone and synergistically with other antifungal drugs was documented *in vitro*, likely by inhibiting fungal heat shock protein 90 (Hsp90) expression and Hsp90-related genes. ATRA treatment reduced mortality in a model of IPA *in vivo*. Those findings suggest ATRA as a suitable fungistatic agent that can also reduce dosage and adverse reactions of classical antifungal drugs and add to the development of new therapeutic strategies against IPA and systemic fungal infections.

KEYWORDS  *trans*-retinoic acid, *Aspergillus*, invasive pulmonary aspergillosis, ATRA, aspergillosis, pneumonia

Invasive fungal infection (IFI) is a critical complication in hematologic and neoplastic patients, leading to severe morbidity and mortality (1). IFIs are estimated to be responsible for approximately 1.5 to 2.0 million deaths every year (2). Over the last decades, the incidence of IFIs has increased due to the concurrent growth of immunocompromised patients, the broad use of antibiotics and chemotherapies, bone marrow and organ transplants, and corticosteroids (2). *Aspergillus fumigatus* is among the most invasive opportunistic pathogens in immunocompromised patients, and the incidence of *Aspergillus*-related IFIs is progressively growing (3). The genus *Aspergillus* includes 4...
subgenera (Aspergillus, Circumdati, Fumigati, and Nidulantes) and 20 sections, including 339 recognized species (4). Nevertheless, only a few well-known species (including Aspergillus fumigatus and Aspergillus flavus) are considered important opportunistic pathogens in both humans and animals (5). In humans, Aspergillus fumigatus is the most common and life-threatening airborne opportunistic fungal pathogen, with particular significance among immunosuppressed hosts (5). Aspergillus fumigatus causes invasive pulmonary aspergillosis (IPA), which is associated with severe morbidity and mortality (5). Despite the high IPA-related mortality, the most used three classes of antifungal drugs (polyenes, azoles, and echinocandins) display limited clinical efficacy and are often unsuccessful, despite the noteworthy side effects associated with their long-term use, the critical pharmacokinetic profile, and, lastly, the drug-drug interactions (6). An important challenge for the future is to discover novel drugs that can also interact with specific fungal targets or modify the existing ones by optimizing their antifungal action by reducing dosages and consequently side effects.

In the last decades, the role of vitamin A in the regulation of the immune response has been confirmed by several studies, and its deficiency is associated with increased susceptibility to severe infectious diseases (7). Vitamin A is a nutrient obtained through the diet either as provitamin A (carotenoids) or as preformed vitamin A (retinol and retinyl esters), and liver dehydrogenases convert retinol into retinoic acid, its biologically active metabolite (7). Retinoids are key modulators of cell growth, differentiation, and apoptosis through their receptor-regulated signaling pathways (8). In particular, retinoic acid controls the normal immune system development as a modulator of both innate and adaptive immune responses (9). We recently documented that the topical use of the retinoid derivative tazarotene favors rapid healing of fungal nail infections (10); moreover, all-trans retinoic acid (ATRA) demonstrated fungistatic activity in vitro (11). Based on this evidence, we sought to evaluate ATRA synergistic interaction with conventional antifungal drugs such as amphotericin B and posaconazole in in vitro studies and its therapeutic efficacy in a preclinical model of IPA.

RESULTS

ATRA displays fungistatic activity on Aspergillus fumigatus germination in vitro. At 0.5 to 1 mM concentration, ATRA exerted a strong inhibitory effect on swelling and germination of Aspergillus conidia in vitro (Fig. 1A and B) as previously reported (11). After 18 h of treatment with lower ATRA concentrations (0.25 and 0.125 mM), Aspergillus conidia appeared swollen (Fig. 1C and D) and similar to control, but without the development of short germ tubes typical of control cultures (Fig. 1E). The inhibitory effect on conidial germination was maintained until 30 h (Fig. 1F and G). At that time, ATRA at concentrations lower than 0.5 mM did not interfere with Aspergillus conidia germination, although the development of germ tubes appeared delayed (Fig. 1H and I). Only control Aspergillus cultures (Fig. 1L) displayed elongated hyphal structures. The fungistatic effect of ATRA was reversible since conidia were able to germinate and to grow in the hyphal form 7 days after ATRA removal (data not shown).

ATRA exerts a synergistic fungistatic activity with amphotericin B and posaconazole in vitro. In order to investigate the synergistic fungistatic activity of ATRA with standard antifungal drugs, we determined a subinhibitory concentration of amphotericin B (AmB). As shown in Fig. 2A, 3.15 μg/ml was the minimal AmB concentration capable of inhibiting Aspergillus conidia germination, while at 1.57 μg/ml concentration, AmB did not interfere with germination (Fig. 2B), and only a delayed hyphal growth was observed. Interestingly, the association of low and noneffective doses of ATRA (0.25 or 0.125 mM; Fig. 2C and D) with that subinhibitory dose of AmB (1.57 μg/ml) displayed a synergistic efficacy against Aspergillus conidial swelling and germination after 24 h (Fig. 2E and F). To confirm the synergism of ATRA in combination with AmB or posaconazole (POS), currently used as primary therapy against aspergillosis, antifungal susceptibility tests were also performed in vitro. As shown in Table 1, the lowest concentration of ATRA that caused prominent growth inhibition (MIC ≥ 50) of the fungus was 75 μg/ml (0.25 mM), while MIC values of AmB and POS were 3.15 μg/ml.
and 0.0018 μg/ml, respectively. Of note, both the antifungal drugs showed a synergistic inhibitory effect toward *A. fumigatus* in combination with a low ineffective dose of 35 μg/ml (0.125 mM) of ATRA. Notably, this synergistic interaction was more remarkable with POS. Indeed, the MIC values of AmB and POS combined with ATRA were one dilution and three dilutions lower, respectively, than the MICs of the drugs alone (MIC of AmB plus ATRA, 1.5 μg/ml [versus MIC of AmB alone, 3.15 μg/ml]; MIC of POS plus ATRA, 0.00022 μg/ml [versus MIC of POS alone, 0.0018 μg/ml]). These results suggest a promising interaction in vivo and the therapeutic possibility of reducing classical antifungal drug dosage.

**ATRA reduced mortality in a rat model of invasive pulmonary aspergillosis.** We investigated the efficacy of ATRA in a rat model of IPA, also in comparison with the
antifungal drug posaconazole, commonly used in clinical practice against IPA. Thirty rats were divided into three experimental groups (n = 10), including control, ATRA treated, and posaconazole treated. ATRA dosage and administration protocol (2 mg/kg intraperitoneally), starting 8 days before the infection, were established in a preliminary study (data not shown). Posaconazole treatment (4 mg/kg per os) started concurrently with the infection (12). As shown in Fig. 3, both drugs impacted IPA progression compared to the control group. In particular, 100% of ATRA-treated rats were alive 6 days after the infection. During the second week, ATRA and posaconazole displayed a very similar effect on survival, with 60% of rats alive at the end of the study (P < 0.05 versus control). Those in vivo findings further supported ATRA efficacy as promising for IPA.

**FIG 2** Synergic effect of ATRA and amphotericin B on *Aspergillus fumigatus* conidia germination. (A) Representative images of the effect of AmB and ATRA alone and in combination on *Aspergillus fumigatus* conidia germination, followed using an optical microscope with a ×40 magnification objectives lens. Microscopic images were recorded 30 h after the treatments. One of three representative experiments is shown. Bars indicate 50 μm.

**TABLE 1** Activity of ATRA alone and combined with amphotericin B or posaconazole on *A. fumigatus* growtha

| Substance       | MIC (µg/ml) |
|-----------------|-------------|
| ATRA            | 75          |
| AmB             | 3.15        |
| POS             | 0.0018      |
| ATRA plus AmB   | 1.57        |
| ATRA plus POS   | 0.00022     |

*The MIC is the lowest concentration of ATRA, AmB, or POS alone or in combination at which a prominent decrease in turbidity is observed compared with the drug-free control (≥50% growth inhibition) after 24 h of incubation. In the combination antifungal treatments, ATRA was used at a suboptimal dose of 37.5 μg/ml.*
therapy.

**ATRA enhances macrophage phagocytosis of Aspergillus conidia in vitro.**

Macrophages play a major role in controlling Aspergillus infection (13). In the present study, we also evaluated the capability of ATRA of modulating macrophage phagocytic activity in vitro. As reported in Fig. 4A, ATRA significantly increased conidia phagocytosis by U-937 human macrophages compared to control (at 5 or 10 μM, around 20 and 40%, respectively). Image analysis of macrophage phagocytosis (Fig. 4B) confirmed the increased phagocytosis and adherent macrophage-conidia complex after ATRA treatment (5 and 10 μM). Those data suggested ATRA improves macrophage phagocytosis that likely contributes to antifungal activity against IPA in vivo.

**ATRA inhibits Aspergillus Hsp90 expression and Hsp90-related genes in vitro.**

To confirm whether ATRA is an inhibitor of heat shock protein 90 (Hsp90), Aspergillus conidia were cultured in ATRA-supplemented medium for 24 h. Immunoblot analysis showed that after 24 and 48 h of ATRA (1 mM) treatment, Hsp90 protein expression was almost suppressed (Fig. 5A and B). In the presence of the reduced density and growth rate of Aspergillus conidia, quantitative real-time reverse transcription-PCR (qRT-PCR) documented, in the ATRA-treated group, a strong decrease (about 70%; \( P < 0.05 \)) of Hsp90 transcripts compared to untreated Aspergillus conidia (Fig. 5C). It was previously reported that the expression of the conidiation-specific genes AbaA and WetA is reduced in the presence of Hsp90 inhibitor (14). To confirm that fungistatic activity of ATRA is Hsp90 related, we also quantified the expression of AbaA and WetA; qRT-PCR analysis showed that ATRA-induced and ATRA-reduced conidia formation associates with the inhibition of Hsp90 expression and decreased AbaA (about 60%) and WetA (about 60%) transcripts in Aspergillus cultures (Fig. 5D). Similar results were also observed at 62 μM ATRA concentration (data not shown). Hsp90 is also reported to interact with the catalytic subunit of calcineurin (15), necessary for correct hyphal growth (16). We investigated ATRA-induced inhibition of the calcineurin pathway and quantified the expression of CrzA, a major signaling component of the zinc finger transcription factor. CrzA expression was strongly reduced (about 40%) in the presence of ATRA (Fig. 5D). Those data demonstrated that ATRA is a potent inhibitor of fungal Hsp90 expression and Hsp90-related genes and that its inhibition likely contributes to the fungistatic activity of ATRA against Aspergillus in vitro.

**Heat shock protein 90 ATP-binding site is a target of ATRA.**

Hsp90 is a chaperone protein required for the activation and stabilization of a wide variety of client proteins, many of them involved in crucial cellular pathways (17). In the absence of *A. fumigatus* Hsp90 X-ray structure, the crystal structure of Hsp90 from *Saccharomyces cerevisiae*, with PDB ID 2CG9 (18), whose sequence shares around 78% of identity and 95% of query cover with *A. fumigatus*, has been used as a template to generate the *A. fumigatus* Hsp90 model structure (Fig. 6A). A structural bioinformatic analysis was performed to investigate whether Hsp90 may be an ATRA-specific pharmacological target against Aspergillus growth. The ATRA structure, as observed with the ATP molecule, completely

---

**FIG 3** ATRA and posaconazole show a similar efficacy in a rat model of invasive pulmonary aspergillosis. Kaplan-Meier analysis of overall survival of 10 rats/group treated with ATRA (2 mg/kg i.p.), posaconazole (4 mg/kg per os), or vehicle (control group). Statistical significance of ATRA and posaconazole treatments versus control group was evaluated by log-rank test analysis; *, \( P = 0.05 \).
filled the Hsp90 ATP-binding site in the N-terminal domain of the *Aspergillus fumigatus* model structure (Fig. 6B and C). In particular, the trimethylcyclohexene moiety was located at the bottom of the ATP-binding site, fully stabilized by hydrophobic contacts with the residues (Fig. 6B and C) (19), while the carboxyl-terminal group was involved in hydrogen bonds with residue Arg98 located at the external border of the ATP-binding site. The interaction energy, evaluated by molecular docking simulation, was around $-28.9$ kcal/mol, a value only slightly below that obtained using the same procedure with the ATP molecule ($-29.7$ kcal/mol). These results strongly supported that ATRA molecule may be considered a competitive inhibitor of the Hsp90 ATP-binding site, in particular at high concentrations, and further confirm Hsp90 as a target of ATRA-induced fungistatic activity.

**DISCUSSION**

Over the last decades, the incidence of IFIs constantly increased. Moreover, the use
of fungicidal drugs in the treatment of fungal diseases led to the development of resistance burden (20). Here, we documented that ATRA displayed a strong fungistatic activity in Aspergillus cultures and reduced mortality in a model of IPA in cortisone acetate-immunosuppressed rats. Our preliminary data also showed that the therapeutic benefit of ATRA is dose dependent and, most importantly, the outcome comparable to that obtained with posaconazole, used as the current standard care for the treatment of IPA. Our in vitro and in vivo findings help to explain some observations previously reported in the clinical practice. In leukemic patients treated with ATRA and other drugs, a lower occurrence of overall fungaemic events has been observed (21, 22). Thus, the low clinical incidence of fungal infections is likely linked to the ability of ATRA to rapidly differentiate leukemic promyelocytes (23) but, more importantly, to its direct antifungal and immunomodulatory properties. In this light, we also documented a synergistic therapeutic activity of suboptimal doses of ATRA combined with the subinhibitory concentration of the antifungal drug amphotericin B against Aspergillus conidia germination. This promising interaction could provide an important potential advantage with the use of ATRA in clinical practice, allowing for reduction of the dosage of classic antifungal drugs with a greater control of their side effects as well as a potential better control of the development of fungal drug resistance. However, further experimental in vivo studies are required to establish an optimal therapeutic protocol for the use of ATRA in association with antifungal drugs against IPA and systemic Aspergillus infections.

It is well-known that conidial germination represents a crucial step in the pathogenesis and progression of IPA. Alveolar macrophages are the first important line of the host’s immune defense against Aspergillus conidia. In healthy individuals, lung resident macrophages are able to rapidly engulf and kill inhaled conidia and are not capable of internalizing hyphal cells (24). In immunocompromised patients, nonphagocytosed conidia produce germ tubes that elongate into hyphae in the lung tissue, causing a

---

**FIG 5** ATRA inhibits the heat shock Hsp90 protein and mRNA expression of Aspergillus. Representative blots (A) and bar graphs (B) of densitometric evaluation of Hsp90 protein expression on Aspergillus conidia treated with ATRA. Aspergillus conidia were cultured in L15 with 2% FCS at 37°C for 24 h in the presence of 1 mM ATRA. The average and SEM of triplicate experiments are shown. Significant changes are reported as \( P < 0.001 \) (***) (Student’s t test). (C) Hsp90 mRNA expression level assessed by qRT-PCR and normalized to untreated Aspergillus conidia. (D) CrzA, WetA, and AbaA mRNA levels assessed by qRT-PCR and normalized to untreated Aspergillus conidia. The expression ratios were normalized to elongation factor 1α expression and were calculated according to the threshold cycle (ΔΔC\text{t}) method. All experiments were performed in triplicate, and data were presented as the mean ± SEM. **, \( P < 0.01 \); ***, \( P < 0.001 \); Student’s t test.
systemic infection for their capacity to invade blood vessels. Here, we demonstrated that ATRA increases, in a dose-dependent manner, the number of adherent and internalized resting *Aspergillus* conidia by macrophages, suggesting its modulatory action on innate immunity. Our results were in line with previous studies showing that ATRA is able to enhance macrophage phagocytosis against *Candida* yeasts and to favor

**FIG 6** Heat shock protein 90 is a pharmacological target of ATRA. (A) Structural model of *Aspergillus fumigatus* Hsp90 dimeric structure. Magnification of *Aspergillus fumigatus* ATP-binding site, including the ATP molecule from the template, colored by atom type (right). (B) Schematic view of the best molecular docking complexes between Hsp90 *Aspergillus fumigatus*. ATP (left) and ATRA molecule (right). The hydrogen bonds have been indicated with green dashed lines between the interaction partners. The residues composing the active sites that are in proximity of the molecules are shown. Images have been produced using the LigPlot+ software. (C) Best molecular docking complexes between *Aspergillus fumigatus* Hsp90 with ATP (left) and ATRA molecules (right). The $\alpha$-helices and loops are shown as light blue spirals and wires, respectively. The molecular surface is shown, and the ligand molecules, hosted in the Hsp90 ATP-binding site, are depicted by sphere representations. Panels A and C have been produced using the Chimera program.
healing of pneumonia by *Pneumocystis carinii* in an affected patient (23, 25). ATRA, by suppressing the conidial germination and hyphal growth, could exert a crucial role in facilitating the conidia uptake and their elimination by phagocytic cells, preventing the spread of infection as well as host tissue damage caused by hyphal invasion. Considering the crucial role of macrophages in *Aspergillus* conidia clearance and that the phagocytic activity is impaired in severely immunocompromised patients, the impact of ATRA on phagocytic activity of macrophages is quite relevant. Recent studies also support the hypothesis that efficacy of vitamin A and ATRA alone or in combination with other drugs is related to the capacity to stimulate the monocyte-mediated immune response (26).

Recent works indicate that fungal Hsps are implicated in several processes, including pathogenicity, phase transition, and antifungal drug resistance (27). The function of Hsp90 in *Aspergillus* has been also investigated, and genetic and pharmacologic studies indicate an important role of Hsps in conidiation and in cell wall stress-compensatory mechanisms (27). Here, we report a reduced Hsp90 expression in ATRA-treated *Aspergillus* conidia cultures. Thus, Hsp90 could represent an important target for inhibiting replication and controlling fungal drug resistance. It was demonstrated that Hsp90 itself is subjected to posttranslational modification in a cell cycle-dependent manner. In *S. cerevisiae*, during the S phase of the cell cycle, the tyrosine kinase Swe1 phosphorylates a residue in the N terminus of Hsp90 that facilitates chaperone interaction with numerous client proteins (28). A role for Hsp90 in *Candida albicans* cell cycle progression has been also established and a molecular link between Hsp90, cell cycle regulation, and morphogenesis defined, identifying Hsp90 as an important player in cell cycle progression (29). Besides Hsp90, our results showed that ATRA downregulates transcription of other genes, in particular, AbAa and WetA. Their inhibition is reported in association with decreased conidia formation (30). We documented the downregulation of CrzA expression in ATRA-treated *Aspergillus* cultures. CrzA is involved in the calcineurin pathway and hyphal growth (31).

In order to better elucidate how ATRA targets the expression of Hsp90, molecular docking demonstrated that ATRA can fit the Hsp90 ATP-binding site in the N-terminal domain of the *Aspergillus fumigatus* model structure. Hsp90 is an ATP-dependent molecular chaperone which is essential in eukaryotes. Hsp90 is required for the activation and stabilization of a wide variety of client proteins, and many of them are involved in important cellular pathways (32). Structurally, Hsp90 is a flexible dimeric protein composed of three different domains which adopt structurally distinct conformations. ATP binding triggers directionality in these conformational changes and leads to a more compact state. Posttranslational modifications of Hsp90, such as phosphorylation and acetylation, may provide another level of its regulation. Phosphorylation and acetylation influence the conformational cycle, cochaperone interaction, and interdomain communications (33). Targeting Hsp90 to reduce stress response compensatory pathways with fungal-specific inhibitors of ATRA may represent an attractive novel antifungal strategy (34).

In conclusion, we documented the efficacy of ATRA in a rat model of IPA and its synergistic capacity to improve the efficacy of antifungal agents *in vitro*. ATRA, for its direct fungistatic action targeting the expression of fungal Hsp90, combined with its immunoadjuvant effect against opportunistic fungi, may represent a promising novel candidate in the armamentarium of systemic therapeutic strategies for the treatment and/or prophylaxis of IPA and IFIs, either alone or in association with conventional antifungal drugs.

**MATERIALS AND METHODS**

**Microorganism and fungal cultures and treatments.** The *Aspergillus fumigatus* strain obtained from a clinical isolate, according to routine hospital laboratory procedures, was grown on Sabouraud dextrose agar (SDA) (Difco, Detroit, MI) supplemented with chloramphenicol. Resting conidia were obtained from the SDA-grown fungal culture as previously described (11). For *in vitro* studies, ATRA (catalog no. R2625; Sigma-Aldrich, Milan, Italy) and amphotericin B (Fungizone) (Sigma-Aldrich, Milan, Italy) were tested in the range of 1 to 0.06 mM (300 to 37.5 μg/ml) and in the range of 50 to 0.09 μg/ml,
respectively. To investigate the potential synergistic interaction between ATRA and AMB on the conidial germination, resting conidia were plated at the density of $1 \times 10^4$ in 96-well microplate in RPMI 1640 with 10% fetal calf serum (FCS; Euroclone, Milan, Italy), supplemented with penicillin (100 U/ml) and streptomycin (100 $\mu$g/ml) and treated with different concentrations of ATRA or Amb, alone or in combination. In the combined treatment, ATRA was given 30 min before amphotericin B. Fungal cultures were maintained at 37°C and monitored during the first 30 h after the treatments.

**Evaluation of fungicidal activity.** Aspergillus fumigatus development was followed using an optical microscope (Carl Zeiss, UK) with a x40 magnification objectives lens. Aspergillus conidia vitality was evaluated microscopically by the trypan blue dye exclusion method.

**In vitro antifungal susceptibility testing.** The synergistic antifungal activity of ATRA in combination with the antifungals Amb or POS (Sigma-Aldrich) against Aspergillus fumigatus was also assessed using the broth microdilution method as described in M38-A2, a document produced by the Clinical Laboratory Standards Institute (35). RPMI 1640 2% glucose with L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) buffered to pH 7.0 was used as fungal culture medium. A. fumigatus strain was grown on Sabouraud dextrose agar (Difco Laboratories, Detroit, MI, USA) supplemented with chloramphenicol. Resting conidia were harvested by washing the slant cultures with sterile saline as previously described (11). Aspergillus inoculum was set to $0.4 \times 10^3$ to $0.5 \times 10^5$ CFU/ml, standardized spectrophotometrically. We added 100 $\mu$l of this suspension to 96-well flat-bottom plates. Twofold serial dilutions of ATRA (from 150 $\mu$g/ml to 37.5 $\mu$g/ml), Amb (from 50 $\mu$g/ml to 0.09 $\mu$g/ml), and POS (4 $\mu$g/ml to 0.00005 $\mu$g/ml) were prepared in RPMI 1640 medium. Aspergillus conidia were treated with 100 $\mu$l of each antifungal drug either alone or in combination with ATRA. Positive (100 $\mu$l of RPMI medium with 100 $\mu$l of conidia) and negative controls (200 $\mu$l of RPMI containing ATRA alone or in association with the antifungals without conidia) were included in all experiments. The plates were incubated with agitation at 37°C for 24 h. The MIC was determined spectrophotometrically at 510 nm with an enzyme-linked immunosorbent assay (ELISA) reader. For each compound, the MIC was defined as the lowest drug concentration that produced a significant inhibition (MIC $> 50$) of fungal growth compared with the drug-free control. The MICs were tested in three independent experiments carried out in triplicate.

**Animals, fungal infection, and treatment.** Sprague-Dawley rats (Envigo, Huntingdon, UK) were immunosuppressed by cortisone 21-acetate (catalog no. C3130; Sigma-Aldrich, St. Louis, USA) treatment subcutaneously administered at 150 mg/kg body weight 7 days before the day of infection; immunosuppression was maintained with 80 mg/kg of cortisone 21-acetate for 3 days a week until the end of the experiment. As the immunosuppression treatment started and throughout the study, rats received a low-protein (8%) diet, as well as drinking water containing tetracycline hydrochloride antibiotic (260 mg/l) in water at a concentration of 4 mg/10 ml (Merck Sharp & Dohme, Kenilworth, NJ, USA). Posaconazole treatment started concurrently with the infection (day 0), and it was administered for 5 days a week until the end of the study. As a negative control, the vehicle (100 $\mu$l of water) was given daily until the end of the studies. All animal procedures were carried out in accordance with the standards established by the Animal Ethical Committee of Takis.

**Phagocytosis assay.** For phagocytosis assay (36), human macrophages U-937 (1 $\times 10^6$ cells/ml) were incubated overnight in 6-ml polypropylene tubes in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Milan, Italy) supplemented with 2% (vol/vol) FCS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 $\mu$g/ml of streptomycin with vehicle (DMSO) or different ATRA concentrations (1, 5, and 10 $\mu$M). After overnight incubation, the cells were incubated for an additional 1 h at 37°C with unopsonized resting Aspergillus conidia at an effector-to-fungal cells ratio of 1:10 before being evaluated for internalization and visualization by light microscopy. Phagocytic cells were separated from nonphagocytosed A. fumigatus by centrifugation on a fetal serum gradient. A 0.1-ml sample of the harvested phagocytic cells was used for cytoospin preparation. After Diff-Quik staining, fungal cell internalization was expressed according to the following formula: percentage of internalization = number of cells containing one or more fungal cells/100 cells counted. In parallel, macrophage phagocytosis was also performed in 24-well plates for a real-time analysis of phagocytosis by microscopy. U-937 macrophages cultured at 1 $\times 10^6$ cells/ml were treated overnight with ATRA and incubated for an additional 1 h at 37°C with Aspergillus conidia as described above.

**Western blot analysis.** For Western blot analysis, after extraction, 20 $\mu$g of total proteins was blotted onto nitrocellulose membranes and incubated with rabbit anti-Hsp90 (1:1,000; Cell Signaling Technologies, Danvers, MA, USA) and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:20,000; Gentex, Zeeland, MI, USA), followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:2,500; Santa Cruz Biotechnology, Dallas, TX, USA). Revelation and densitometric blot scans were performed in three different experiments.

**RNA extraction and real-time reverse transcription-PCR.** A sample of frozen biomass was placed into a 2-ml extraction tube containing beads and disrupted using TissueLyser. RNA was isolated using TRI reagent (Sigma-Aldrich) according to the manufacturer’s instructions. To verify the general purity of the RNA, a NanoDrop instrument was used. One microgram of total RNA was reverse transcribed by a
QuantiTect reverse transcription kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. qRT-PCR analyses were performed using 20 ng cDNA per well in triplicate with the SYBR Green master mix (Applied Biosystems, Foster City, CA USA) (37, 38) according to the manufacturer’s instructions. Reactions were run on 7900HT system (Applied Biosystems).

Heat shock protein 90 simulation methods. Protein-ligand molecular docking has been used to evaluate binding mode and energy between A. fumigatus Hsp90, ATRA (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl) nona-2,4,6,8-tetraenoic acid) and ATP, its natural cofactor. The docking simulations have been executed using the AutoDock Vina 1.1.2 program through the AutoDock Vina PyMOL plugin (https://www3.mpibpc.mpg.de/groups/de_groot/dseelig/adplugin.html) simulations have been executed using the AutoDock Vina (2,6,6-trimethylcyclohexen-1-yl) nona-2,4,6,8-tetraenoic acid] and ATP, its natural cofactor. The docking have been obtained from the PubChem compound database (https://pubchem.ncbi.nlm.nih.gov) and have been converted into mol2 files and filled with hydrogens using the Open Babel program (https://openbabel.org). The crystal structure of Hsp90 from S. cerevisiae has been used as a template to generate the A. fumigatus Hsp90 model structure. The model has been generated using the SWISS-MODEL protein modeling tool (https://swissmodel.expasy.org) (40). After a structural check, the model has been as a receptor for the molecular docking simulations of ATP and ATRA in the ATP-binding site. Thirteen side chains (Leu34, Asn37, Lys44, Asp79, Ile82, Asp88, Lys102, Gln103, Phe124, Val136, Thr171, and Ile173) belonging to the Hsp90 ATP-binding site have been considered rotatable to improve the conformational search during the docking simulations.

Statistical analysis. For in vitro experiments, statistical analysis was performed using an unpaired two-tailed t test between control and experimental groups. For in vivo studies, survival curves were determined by the Kaplan-Meier method, and the log-rank test was used to conduct comparisons between the groups. Test of statistical significance was two-sided; a value of \( p < 0.05 \) was considered to be statistically significant.

ACKNOWLEDGMENTS

We thank Mariachiara Minerva and Daniela Stoppoloni for their technical assistance. We declare no conflicts of interest.

REFERENCES

1. Brown GD, Denning DW, Levitz SM. 2012. Tackling human fungal infections. Science 336:647, https://doi.org/10.1126/science.1222236.
2. Roemer T, Krysan DJ. 2014. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4a:a019703. https://doi.org/10.1101/cshperspect.a019703.
3. Pfaffer MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit Rev microbiol 36:31–53, https://doi.org/10.1080/1040841090324144A.
4. Hubert RA, Visagie CM, Houbraken J, Hong S-B, Hubika V, Klaassen CHW, Perrone G, Seifert KA, Susca A, Tanney JB, Varga J, Kocsbusi S, Szegiti G, Yaguchi T, Frisvad JC. 2014. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol 78:141–173. https://doi.org/10.1016/j.stmyco.2014.07.004.
5. Kwon-Chung KJ, Sugui JA. 2013. Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog 9:e1003743. https://doi.org/10.1371/journal.ppat.1003743.
6. Roemer T, Krysan DJ. 2014. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4a:a019703. https://doi.org/10.1101/cshperspect.a019703.
7. Claflin-LeMaire D, Knutson D. 2011. Vitamin A in reproduction and development. Nutrients 3:385–428. https://doi.org/10.3390/nu3030385.
8. Dolo E, Costanza G, Ferlosio A, Pompeo E, Agostinelli S, Bellezza G, Mazzaglia D, Giunta A, Sidoni A, Orlandi A. 2015. High expression of cellextracellular signal-regulated kinase 1, 2 (erk1/2) and Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun 72:7330–7333. https://doi.org/10.1128/IAI.02168-14.
9. Kwon-Chung KJ, Sugui JA. 2013. Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog 9:e1003743. https://doi.org/10.1371/journal.ppat.1003743.
10. Campione E, Paternò EJ, Costanza G, Dilluio L, Carboni I, Marino D, Favalli C, Chimienti S, Bianchi L, Orlandi A. 2015. Tazareaone as alternative topical treatment for onychomycosis. Drug Des Devel Ther 9:879–886. https://doi.org/10.2147/DDDT.s93985.
11. Campione E, Gazzano R, Marino D, Orlandi A. 2016. Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans. Drug Des Devel Ther 10:1551–1555. https://doi.org/10.2147/DDDT.s93985.
M. Facchini L, Martino B, Di Blasi R, Cesaroni M, Offidani M, Vianelli N, Caira M, Lessi F, Ardini A, Venditti A, Pavone V, Lo Coco F, Aversa F, Busca A, Sorvegliani Epidemiologica Infezioni Fungine in Emopatie Maligne Group. 2015. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. Br J Haematol 170:434–439. https://doi.org/10.1111/bjh.13308.

23. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Lei G-S, Zhang C, Shao S, Jung H-W, Durant PJ, Lee C-H. 2013. All-trans retinoic acid in combination with primaquine clears pneumocystis infection. PLoS One 8:e3479. 10.1371/journal.pone.003479.

24. Shoham S, Levitz SM. 2005. The immune response to fungal infections. Br J Haematol 129:415–424. https://doi.org/10.1111/j.1365-2141.2005.05397.x.

25. Klassert TE, Hanisch A, Bräuer J, Klaile E, Heyl KA, Mansour MK, Mansour MM, Tam JM, Vyas JM, SlevoGT H. 2014. Modulatory role of vitamin A on the Candida albicans-induced immune response in human monocytes. Med Microbiol Immunol 203:415–424. https://doi.org/10.1007/s00430-014-0351-4.

26. Girmenia C, Lo Coco F, Breccia M, Latagliata R, Spadea A, D’Andrea M, Gentile G, Miccozi G, Alimens G, Martino P, Mandelli F, Fiscelli F. 2003. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia 17:925–930. https://doi.org/10.1038/sj.leu.2402899.

27. Lamoth F, Juvvadi PR, Fortwendel JR, Steinbach WJ. 2012. Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus. Eukaryot Cell 11:1324–1332. https://doi.org/10.1128/EC.00032-12.

28. Mollapour M, Tsutsumi S, Donnelly AC, Lee M-J, Lee S, Moor G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WN, Trepel JB, Piper PW, Prodromou C, Pearl L, Neckers L. 2010. Sae1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 37:333–343. https://doi.org/10.1016/j.molcel.2010.01.005.

29. Senn H, ShapiRO RS, Cowen LE. 2012. Dcd28 provides a molecular link between Hsp90, morphogenesis, and cell cycle progression in Candida albicans. Mol Biol Cell 23:268–283. https://doi.org/10.1091/mbc.E11-08-0729.

30. Tao L, Yu J-H. 2011. AbaA and WetA govern distinct stages of Aspergillus fumigatus development. Microbiology (Reading) 157:313–326. https://doi.org/10.1099/micro.0.044271-0.

31. Juvvadi PR, Lamoth F, Steinbach WJ. 2014. Calcineurin-mediated regulation of hyphal growth, septation, and virulence in Aspergillus fumigatus. Mycopathologia 178:341–348. https://doi.org/10.1007/s11046-014-9794-9.

32. Gaziano R, Campione E, Iacovelli F, Marino D, Pica F, Di Francesco P, Aquaro S, Meninchi F, Falconi M, Bianchi L. 2018. Antifungal activity of Cardioispermum halicacabum L. (Sapindaceae) against Trichophyton rubrum occurs through molecular interaction with fungal Hsp90. Drug Devel Ther 12:2185–2193. https://doi.org/10.2147/DDDT.S155610.

33. Li J, Buchner J. 2013. Structure, function and regulation of the hsp90 machinery. BioMed Res Int 2013:106–117. https://doi.org/10.1155/2013/617230.

34. Cowen LE, Lindquist S. 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309:2185–2189. https://doi.org/10.1126/science.1118370.

35. Rex JH, Ghanounu MA, Alexander BD, Knapp CC, Andes D, Miotyl MR, Arthington-SkaggS B, Ostrosky-Zeichner L, Brown SD, Pfaller M, Sheehan DJ, Walsh TJ. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. CLSI M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.

36. Bozza S, Gazzano R, Spresa A, Bacci A, Montagnoli C, di Francesco P, Romani L. 2002. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 168:1362–1371. https://doi.org/10.4049/jimmunol.168.3.1362.

37. Orlandi A, Francesconi A, Cocchia D, Corsini A, Spagnoli LG. 2001. Phenotypic heterogeneity influences apoptotic susceptibility to retinoic acid and cis-platinum of rat arterial smooth muscle cells in vitro: implications for the evolution of experimental intimal thickening. Arterioscler Thromb Vasc Biol 21:1118–1123. https://doi.org/10.1161/01.ATV.0000070193.2193.

38. Orlandi A, Ciucci A, Ferlosio A, Genta R, Spagnoli LG, Gabbiani G. 2006. Cardiac myxomas exhibit embryonic endocardial stem cell features. J Pathol 209:231–239. https://doi.org/10.1002/path.1959.

39. Seeliger D, de Groot BL. 2010. Ligand docking and binding site analysis of the Candida albicans. Mol Biol Cell 21:1632–1642. https://doi.org/10.1091/mbc.E10-01-0034.

40. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Stadler FK, Goto S, Bork P, Schwede T. 2014. SWISS-MODEL: modulating protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W258–264. https://doi.org/10.1093/nar/gku340.